- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00270114
A Study of the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Undergoing Orthopedic Surgery and Who Have Low Hematocrit Levels (the Percent of Red Blood Cells in Whole Blood)
May 17, 2011 updated by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recombinant Human Erythropoietin (r-HuEPO) in Patients With Low Hematocrit Levels to Facilitate Presurgical Autologous Blood Donation in Patients Undergoing Orthopedic Surgery (An Open-label Dose Finding Study)
The purpose of this study is to evaluate the safety and effectiveness of epoetin alfa and to determine whether epoetin alfa will facilitate self-donation of blood before surgery in patients who have anemia, (as indicated by low hematocrit levels, the percent of red blood cells in whole blood) and who will be undergoing orthopedic surgery.
Epoetin alfa is a genetically engineered protein that stimulates red blood cell production.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Patients undergoing major orthopedic surgery frequently require blood transfusions both during and after the operation.
A large percentage of patients are not able to pre-deposit their own blood for transfusion.
Additionally, when a patient is anemic, as determined by a low hematocrit level, the amount of blood collected from the patient may not be sufficient to satisfy the amount required for transfusion.
Further, complications such as the transmission of infectious diseases are possible with transfusions from other donors.
Agents that can facilitate self-donation and reduce the need for transfusions from others may improve the overall safety of surgery.
Epoetin alfa is a genetically engineered form of a natural hormone, erythropoietin, that is used to treat anemia by stimulating red blood cell production.
This is a randomized, open-label, placebo-controlled, parallel group, multicenter study to evaluate the safety of epoetin alfa and to determine whether epoetin alfa will facilitate the self-deposit of blood by patients who have low hematocrit levels, are undergoing orthopedic total hip replacement surgery, and are expected to require 3 to 4 units of blood during and after surgery.
The study consists of a 5-day screening period when patients' study eligibility is determined, a 21-day treatment and blood collection period, and a period around the time of surgery (that includes recording the patient's blood status before surgery, as well as recording of blood loss and number of self-donated and/or donor-donated units of blood used during or after surgery).
Eligible patients will be randomly assigned to one of four treatment groups: epoetin alfa 300 units/kilogram (U/kg), epoetin alfa 600 U/kg, placebo to match the volume of epoetin alfa 300 U/kg, or placebo to match the volume of epoetin alfa 600 U/kg, by injection into a vein.
Twice as many patients will receive epoetin alfa as will receive placebo.
Patients and the physician will know the group to which an individual patient is assigned.
Study medication will be administered to each patient every 3 to 4 days, for a total of 6 doses during the 21-day treatment period ending just before surgery.
Additionally, all patients will receive 300 milligrams of an iron supplement daily by mouth or by a combination of an iron supplement by mouth and injected into a vein during the 21-day treatment period.
The dose of the iron supplement and need for administration of an iron supplement into a vein will be determined based on a blood test measuring the iron content in the blood after each collection of blood for self-donation.
Patients who are borderline iron-deficient at screening may be given iron injected into a vein 3 to 4 days before the start of the study.
Thereafter, patients will be randomly assigned to receive either a daily oral iron supplement only or both a daily oral iron supplement plus iron injected into a vein after each collection of a unit of blood.
On Day 1, before the first dose of study drug is given, one unit of blood will be collected and stored for self-donated blood transfusion during or after surgery, only from those patients whose red blood cell level shows they are not anemic, as determined by a hematocrit level >=35%.
Every 3 to 4 days thereafter, the patients' blood will be analyzed and one unit of blood will be collected from each patient whose red blood cell level is >=35%.
A maximum of 6 units of blood can be collected during the 3-week period before surgery and stored for self-donation.
If sufficient units for surgery are not collected from a patient, preparations will be made for that patient to receive needed units of blood from donors.
Safety evaluations will include laboratory tests, physical examination, vital signs, and recording of adverse events.
The effectiveness of epoetin alfa will be evaluated by comparing the number of self-donated units of blood collected from each treatment group, the change in hemoglobin, the change in hematocrit (the percent of red blood cells in whole blood), and the number of immature red blood cells from before the start of the study to the end of the study.
The study hypothesis is that treatment with epoetin alfa will facilitate self-donation of blood in patients with low hemoglobin and hematocrit levels who are undergoing orthopedic surgery.
Epoetin alfa 300 units/kilogram (U/kg), epoetin alfa 600 U/kg, or placebo, by injection into a vein; dose given twice weekly starting 3 weeks before surgery and ending just before surgery.
Study Type
Interventional
Enrollment (Actual)
55
Phase
- Phase 2
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients scheduled for hip replacement surgery
- having an anticipated requirement of 3 or more units of blood
- having a hematocrit level <=0.39
- having a hemoglobin level <= 12.5 grams/deciliter
- having laboratory tests within normal ranges, including stool negative for occult blood
Exclusion Criteria:
- Patients with a history of any blood disease
- having signs and symptoms of significant disease/dysfunction, or signs and symptoms of significant ongoing blood loss
- having uncontrolled high blood pressure, or a folate, vitamin B12, or iron deficiency, or signs and symptoms suggestive of an autoimmune disease causing blood to break down and release iron-containing pigment
- taking medication known to suppress the formation of red blood cells within 1 month before the start of the study
- having a history of seizures, or the presence of active inflammatory disease (e.g., rheumatoid arthritis), however, patients with osteoarthritis may be included in this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Number of self-donated units of blood and the total volume of red blood cells donated; Number of blood units from other donors used for transfusion during surgery
|
Secondary Outcome Measures
Outcome Measure |
---|
Changes in hemoglobin, hematocrit, red blood cell count, and effects of oral iron versus oral plus intravenous iron from before the study to the end of study; Assessment laboratory tests, vital signs, physical examination, and adverse events
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Completion (Actual)
March 1, 1991
Study Registration Dates
First Submitted
December 22, 2005
First Submitted That Met QC Criteria
December 22, 2005
First Posted (Estimate)
December 26, 2005
Study Record Updates
Last Update Posted (Estimate)
May 18, 2011
Last Update Submitted That Met QC Criteria
May 17, 2011
Last Verified
April 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR005914
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Abdelwahed, Mai Mahmoud Mohamed, M.D.UnknownAnemia During PregnancyEgypt
-
University of California, DavisInstituto Mexicano del Seguro Social; Thrasher Research Fund; Mexican National... and other collaboratorsCompleted
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Peking Union Medical College HospitalRecruiting
-
Alexion PharmaceuticalsWithdrawnWarm Autoimmune Hemolytic AnemiaUnited States
Clinical Trials on epoetin alfa
-
Hospital de Clinicas de Porto AlegreOswaldo Cruz Foundation; Rio Grande do Sul State Health Department - SES/RSCompletedComparison of the Efficacy of Two Formulations of Epoetin in Patients Undergoing Hemodialysis
-
MegalabsAzidus LaboratoriesNot yet recruitingAnemia of Chronic Kidney DiseaseUruguay
-
M.D. Anderson Cancer CenterCompleted
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech, Inc.Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech Products, L.P.CompletedKidney Diseases | Anemia
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedBlood Transfusion | Orthopedic Surgery | Orthopedic Procedures | Mammaplasty | Cardiovascular Surgical Procedures | Blood Transfusion, Autologous
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech Products, L.P.Terminated
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech Products, L.P.CompletedCritical Illness | Anemia
-
Johnson & Johnson Pharmaceutical Research & Development...Completed